Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly

References

• Lloyd-JonesDAdamsRJBrownTMHeart Disease and Stroke Statistics – 2010. Update: A Report from the American Heart Association. Statistics Committee and Stroke Statistics SubcommitteeCirculation20101217e46e21520019324
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJBoschJDaviesRDagenaisGThe Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patientsN Engl J Med2000342314515310639539
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study InvestigatorsEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudyLancet2000355920025325910675071
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRJoint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension20034261206125214656957
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRNational Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 reportJAMA2003289192560257212748199
   PubMed Web of Science ®Google Scholar
• RosendorffCBlackHRCannonCPAmerican Heart AssociationCouncil for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and PreventionCirculation20071152127612788
   Google Scholar
• ManciaGde BackerGDominiczakA2007Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Eur Heart J200728121462153617562668
   PubMed Web of Science ®Google Scholar
• CalhounDAJonesDTextorSResistant hypertension: Diagnosis, evaluation, and treatment A scientific statement from the American Heart Association. Professional Education Committee of the Council for High Blood Pressure ResearchHypertension20085161403141918391085
   PubMed Web of Science ®Google Scholar
• BensonSCPershadsinghHAHoCIIdentification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activityHypertension2004435993100215007034
   PubMed Web of Science ®Google Scholar
• VitaleCMercuroGCastiglioniCMetabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndromeCardiovasc Diabetol2005461315892894
   PubMed Web of Science ®Google Scholar
• ScaleraFMartens-LobenhofferJBukowskaALendeckelUTägerMBode-BögerSMEffect of telmisartan on nitric oxide – asymmetrical dimethylarginine system: Role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial agingHypertension200851369670318250362
   PubMed Web of Science ®Google Scholar
• SaitohYHongweiWUenoHMizutaMNakazatoMTelmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cellsDiabetes Metab200935539239719713141
   PubMed Web of Science ®Google Scholar
• JungADKimWParkSHThe effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertensionKorean Circ J200939518018419949576
   PubMedGoogle Scholar
• SinghSLokeYKFurbergCDThiazolidinediones and heart failure: A teleo-analysisDiabetes Care20073082148215317536074
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJONTARGET InvestigatorsTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• YusufSDienerHCSaccoRLTelmisartan to prevent recurrent stroke and cardiovascular eventsNew Engl J Med2008359121225123718753639
   PubMed Web of Science ®Google Scholar
• YusufSTeoKAndersonCTelmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trialLancet200837296441174118318757085
   PubMed Web of Science ®Google Scholar
• VerdecchiaPSleightPManciaGONTARGET/TRANSCEND InvestigatorsEffects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular DiseaseCirculation2009120141380138919770395
   PubMed Web of Science ®Google Scholar
• KarlbergBELinsLEHermanssonKEfficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study GroupJ Hypertens199917229330210067800
   PubMed Web of Science ®Google Scholar
• NakayamaTMasubuchiYKawauchiKBeneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarctionProstaglandins Leukot Essent Fatty Acids2007309634
   Google Scholar
• AsmarRGossePTopouchianJN’telaGDudleyAShepherdGLEffects of telmisartan on arterial stiffness in type 2 diabetes patients with essential hypertensionJ Renin Angiotensin Aldosterone Syst20023317618012563568
   PubMed Web of Science ®Google Scholar
• FormosaVBellomoAIoriAThe treatment of hypertension with telmisartan in the sphere of circadian rhythm in metabolic syndrome in the elderlyArch Gerontol Geriatr200949Suppl 19510119836621
   PubMed Web of Science ®Google Scholar
• JugduttBIAging and remodeling during healing of the wounded heart: Current therapies and novel drug targetsCurr Drug Targets20089432534418393826
   PubMed Web of Science ®Google Scholar
• JugduttBIAging and heart failure: Changing demographics and implications for therapy in the elderlyHeart Fail Rev201015540140520364319
   PubMed Web of Science ®Google Scholar
• GoldbergRJMcCormickDGurwitzJHAge-related trends in short- and long-term survival after acute myocardial infarction: A 20-year population-based perspective 1975–1995Am J Cardiol19988211131113179856911
   PubMed Web of Science ®Google Scholar
• DavisBRVogtTFrostPHRisk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research GroupStroke1998297133313409660383
   PubMed Web of Science ®Google Scholar
• WolfPAD’AgostinoRBBelangerAJKannelWBProbability of stroke: A risk profile from the Framingham StudyStroke19912233123182003301
   PubMed Web of Science ®Google Scholar
• WhiteHDSimesRJAndersonNEPravastatin therapy and the risk of strokeN Engl J Med2000343531732610922421
   PubMed Web of Science ®Google Scholar
• YusufSHawkenSOunpuuSINTERHEART Study InvestigatorsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control studyLancet2004364943893795215364185
   PubMed Web of Science ®Google Scholar
• JelaniAJugduttBISTEMI and heart failure in the elderly: Role of adverse remodelingHeart Fail Rev201015551352120549342
   PubMed Web of Science ®Google Scholar
• WolfPAD’AgostinoRBO’NealMASecular trends in stroke incidence and mortality. The Framingham StudyStroke19922311155115551440701
   PubMed Web of Science ®Google Scholar
• TurnbullFBlood Pressure Lowering Treatment Trialists’ CollaborationEffects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trialsLancet200336293951527153514615107
   PubMed Web of Science ®Google Scholar
• TehraniFPhanAChienCVMorrisseyRPRafiqueAMSchwarzERValue of medical therapy in patients >80 years of age with heart failure and preserved ejection fractionAm J Cardiol2009103682983319268740
   PubMed Web of Science ®Google Scholar
• JugduttBIHeart failure in the elderly: Advances and challengesExpert Rev Cardiovasc Ther20108569571520450303
   PubMedGoogle Scholar
• KannelWBMcGeeDLDiabetes and cardiovascular disease. The Framingham studyJAMA19792411920352038430798
   PubMed Web of Science ®Google Scholar
• WingardDLBarrett-ConnorEHeart disease and diabetesHarrisMJCowieCCSternMSBoykoEJReiberGEBennettPHDiabetes in America2nd edWashington, DCNational Institutes of Health1995
   Google Scholar
• GuKCowieCCHarrisMIDiabetes and decline in heart disease mortality in US adultsJAMA1999281141291129710208144
   PubMed Web of Science ®Google Scholar
• FowlerMJMicrovascular and macrovascular complications of diabetesClin Diabetes20082627782
   Google Scholar
• LonnEMYusufSJhaPEmerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protectionCirculation1994904205620697923694
   PubMed Web of Science ®Google Scholar
• The SOLVD InvestigatorsEffect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failureN Engl J Med199132552933022057034
   PubMed Web of Science ®Google Scholar
• PfefferMABraunwaldEMoyéLAEffect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE InvestigatorsN Engl J Med1992327106696771386652
   PubMed Web of Science ®Google Scholar
• FoxKMThe EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease InvestigatorsEfficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)Lancet2003362938678278813678872
   PubMed Web of Science ®Google Scholar
• PittBO’NeillBFeldmanRQUIET Study GroupThe QUinapril Ischemic Event Trial (QUIET): Evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular functionAm J Cardiol20018791058106311348602
   PubMed Web of Science ®Google Scholar
• BraunwaldEDomanskiMJFowlerSEPEACE Trial InvestigatorsAngiotensin-converting-enzyme inhibition in stable coronary artery diseaseN Engl J Med200336220782788
   Google Scholar
• DagenaisGRPogueJFoxKSimoonsMLYusufSAngiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trialsLancet2006368953558158816905022
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGBainRPRohdeRDThe effect of angiotensin-converting- enzyme inhibition on diabetic nephropathy. The Collaborative Study GroupN Engl J Med199332920145614628413456
   PubMed Web of Science ®Google Scholar
• BoschJLonnEPogueJArnoldJMDagenaisGRYusufSHOPE/HOPE-TOO Study InvestigatorsLong-term effects of ramipril on cardiovascular events and on diabetes: Results of the HOPE study extensionCirculation200511291339134616129815
   PubMed Web of Science ®Google Scholar
• PatelAADVANCE Collaborative GroupEffects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trialLancet2007370959082984017765963
   PubMed Web of Science ®Google Scholar
• JugduttBIValsartan in the treatment of heart attack survivorsVasc Health Risk Manag20062212513817319456
   PubMedGoogle Scholar
• KjeldsenSELylePATershakovecAMTargeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockersExpert Opin Emerg Drugs200510472974516262560
   PubMedGoogle Scholar
• StraussMHHallASAngiotensin receptor blockers may increase risk of myocardial infarction: Unraveling the ARB-MI paradoxCirculation2006114883885416923768
   PubMed Web of Science ®Google Scholar
• CampbellDJKrumHEslerMDLosartan increases bradykinin levels in hypertensive humansCirculation2005111331532015655136
   PubMed Web of Science ®Google Scholar
• McKelvieRSYusufSPericakDComparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study InvestigatorsCirculation1999100101056106410477530
   PubMed Web of Science ®Google Scholar
• TikkanenIOmvikPJensenHAComparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertensionJ Hypertens19951311134313518984133
   PubMed Web of Science ®Google Scholar
• HolwerdaNJFogariRAngeliPValsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared with placebo and enalaprilJ Hypertens1996149114711518986917
   PubMed Web of Science ®Google Scholar
• ChanPTomlinsonBHuangTYKoJTLinTSLeeYSDouble-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced coughJ Clin Pharmacol19973732532579089428
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSCHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: The CHARM-Alternative trialLancet2003362938677277613678870
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGfor the Valsartan Heart Failure Trial InvestigatorsA randomized trial of angiotensin receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKCHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting- enzyme inhibitors: The CHARM-Added trialLancet2003362938676777113678869
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSELIFE Study GroupCardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• DicksteinKKjekshusJOPTIMAAL Steering Committee of the OPTIMAAL Study GroupEffects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist LosartanLancet2002360933575276012241832
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan in Acute Myocardial Infarction Trial InvestigatorsValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• VolpeMManciaGTrimarcoBAngiotensin II receptor blockers and myocardial infarction: Deeds and misdeedsJ Hypertens200523122113211816269950
   PubMed Web of Science ®Google Scholar
• RiesUJMihmGNarrB6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: Synthesis, biological activity, and structure-activity relationshipsJ Med Chem19933625404040518258826
   PubMed Web of Science ®Google Scholar
• SmithDHGNeutelJMMorgensternPOnce-daily telmisartan compared with enalapril in the treatment of hypertensionAdv Ther199815229240
   Google Scholar
• NeutelJMSmithDHGDose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertensionAdv Ther199815206217
   Web of Science ®Google Scholar
• LarsenPDMartinJLPolypharmacy and elderly patientsAORN J19996936192262562762811957456
   PubMedGoogle Scholar
• JonesBADecreasing polypharmacy in clients most at riskAACN Clin Issues1997846276349392719
   PubMedGoogle Scholar
• BurrellLMJohnstonCIAngiotensin II receptor antagonists. Potential in elderly patients with cardiovascular diseaseDrugs Aging19971064214349205848
   PubMed Web of Science ®Google Scholar
• PicardFAuwerxJPPAR (gamma) and glucose homeostasisAnnu Rev Nutr20022216719712055342
   PubMed Web of Science ®Google Scholar
• WalczakRTontonozPPPARadigms and PPARadoxes: Expanding roles for PPARgamma in the control of lipid metabolismJ Lipid Res200243217718611861659
   PubMed Web of Science ®Google Scholar
• WakinoSLawREHsuehWAVascular protective effects by activation of nuclear receptor PPAR gammaJ Diabetes Complications2002161464911872366
   PubMed Web of Science ®Google Scholar
• HsuehWALawRThe central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular diseaseAm J Cardiol.2003924A3J9J
   Web of Science ®Google Scholar
• SchiffrinELAmiriFBenkiraneKIglarzMDiepQNPeroxisome proliferator-activated receptors: Vascular and cardiac effects in hypertensionHypertension200342466466812874098
   PubMedGoogle Scholar
• KotchenTAAttenuation of hypertension by insulin-sensitizing agentsHypertension19962822192238707385
   PubMed Web of Science ®Google Scholar
• VermaSBhanotSArikawaEYaoLMcNeillJHDirect vasodepressor effects of pioglitazone in spontaneously hypertensive ratsPharmacology19985617169467183
   PubMed Web of Science ®Google Scholar
• BuchananTAMeehanWPJengYYBlood pressure lowering by pioglitazone. Evidence for a direct vascular effectJ Clin Invest19959613543607615805
   PubMed Web of Science ®Google Scholar
• NestoRWBellDBonowROThiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes AssociationDiabetes Care200427125626314693998
   PubMed Web of Science ®Google Scholar
• ShiomiTTsutsuiHHayashidaniSPioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarctionCirculation2002106243126313212473562
   PubMed Web of Science ®Google Scholar
• CaoZYePLongCEffect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in ratsPharmacology200779318419217356310
   PubMed Web of Science ®Google Scholar
• YueTLChenJBaoWIn vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazoneCirculation2001104212588259411714655
   PubMed Web of Science ®Google Scholar
• LygateCAHulbertKMonfaredMThe PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarctionCardiovasc Res200358363263712798436
   PubMed Web of Science ®Google Scholar
• GrahamDJOuellet-HellstromRMaCurdyTERisk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazoneJAMA2010304441141820584880
   PubMed Web of Science ®Google Scholar
• ZhangHZhangAKohanDENelsonRDGonzalezFJYangTCollecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retentionProc Natl Acad Sci U S A2005102269406941115956187
   PubMed Web of Science ®Google Scholar
• ParhoferKGMünzelFKreklerMEffect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: The DO-IT prospective observational studyCardiovasc Diabetol200763618042288
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDRENAAL Study InvestigatorsEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• NaitoTMaLJYangHAngiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosisAm J Physiol Renal Physiol20102983F683F69120042458
   PubMed Web of Science ®Google Scholar
• BarnettAPreventing renal complications in type 2 diabetes: Results of the diabetes exposed to telmisartan and enalapril trialJ Am Soc Nephrol.2006174 Suppl 2S132S13516565237
   PubMed Web of Science ®Google Scholar
• PhillipsCOKashaniAKoDKFrancisGKrumholzHMAdverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: A quantitative review of data from randomized clinical trialsArch Intern Med2007167181930193617923591
   PubMedGoogle Scholar
• JugduttBIMyocardial salvage by intravenous nitroglycerin in conscious dogs: Loss of beneficial effect with marked nitroglycerin-induced hypotensionCirculation19836836736846409447
   PubMed Web of Science ®Google Scholar
• JugduttBIWarnicaJWIntravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct locationCirculation19887849069193139326
   PubMed Web of Science ®Google Scholar
• JugduttBIWarnicaJWTolerance with low dose intravenous nitroglycerin therapy in acute myocardial infarctionAm J Cardiol198964105815872506751
   PubMed Web of Science ®Google Scholar
• JugduttBIIntravenous nitroglycerin unloading in acute myocardial infarctionAm J Cardiol19916814D52D63
   Web of Science ®Google Scholar
• CruickshankJMThorpJMZachariasFJBenefits and potential harm of lowering high blood pressureLancet1987185335815842881129
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMfor the VALUE trial groupOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• BoschJYusufSGersteinHCDREAM Trial InvestigatorsEffect of ramipril on the incidence of diabetesN Engl J Med2006355151551156216980380
   PubMed Web of Science ®Google Scholar
• DienerHCSaccoRLYusufSPrevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study groupEffects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: A double-blind, active and placebo-controlled studyLancet Neurol200871087588418757238
   PubMed Web of Science ®Google Scholar
• VermaSStraussMAngiotensin receptor blockers and myocardial infarctionBMJ200432974771248124915564232
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative GroupRandomised trial of a perindopril- based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attackLancet2001359928710331041
   Google Scholar
• SchraderJLüdersSKulschewskiAMOSES Study GroupMorbidity and Mortality After Stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES)Stroke20053661218122615879332
   PubMed Web of Science ®Google Scholar
• SchraderJLüdersSKulschewskiAAcute Candesartan Cilexetil Therapy in Stroke Survivors Study GroupThe ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke SurvivorsStroke20033471699170312817109
   PubMed Web of Science ®Google Scholar
• YusufSGersteinHHoogwerfBHOPE Study InvestigatorsRamipril and the development of diabetesJAMA2001286151882188511597291
   PubMed Web of Science ®Google Scholar
• ElliottWJMeyerPMIncident diabetes in clinical trials of antihypertensive drugs: A network meta-analysisLancet2007369955720120717240286
   PubMed Web of Science ®Google Scholar
• CuspidiCMuiesanMLValagussaLCATCH investigatorsComparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: The candesartan assessment in the treatment of cardiac hypertrophy (CATCH) studyJ Hypertens200220112293230012409969
   PubMed Web of Science ®Google Scholar
• CowanBPYoungAAAndersonCLeft ventricular mass and volume with telmisartan, ramipril, or combination in patients at high risk for vascular events: The Cardiac MRI sub-study to ONTARGETAm J Cardiol2009104111484148919932779
   PubMed Web of Science ®Google Scholar
• MannJFSchmiederREMcQueenMONTARGET investigatorsRenal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trialLancet2008372963854755318707986
   PubMed Web of Science ®Google Scholar
• ZouZXiGLYuanHBZhuQFShiXYTelmisartan versus angio-tension-converting enzyme inhibitors in the treatment of hypertension: A meta-analysis of randomized controlled trialsJ Hum Hypertens200923533934918987649
   PubMed Web of Science ®Google Scholar